A clinical trial to study the effect of insulin glargine injection given earlier during diabetic ketoacidosis (DKA) along with regular treatment as compared to regular treatment alone in children with Type-1 Diabetes
- Conditions
- Health Condition 1: E101- Type 1 diabetes mellitus with ketoacidosis
- Registration Number
- CTRI/2022/11/047612
- Lead Sponsor
- Aster Intramural funding
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Males or females presenting with a known history of or presumed new onset type 1 diabetes with diabetic ketoacidosis.
Diabetic ketoacidosis is defined as serum glucose more than 200 mg/dl, venous pH less than 7.3 or serum bicarbonate less than 15mmol/l, ketonemia which is blood beta-hydroxybutyrate levels more than or equal to 3mmol/l or moderate to large ketonuria
Participants who have begun insulin treatment prior to being approached for enrolment
Participants with known diagnosis of type2 diabetes, other specific types such as monogenic diabetes, genetic defects in insulin action, diseases of exocrine pancreas, endocrinopathies, drug or chemical induced insulin resistance and deficiency
Other genetic syndromes associated with diabetes
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method